Terminated PHASE3 INTERVENTIONAL 2-arm NCT01892345

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorder

Interventions Eculizumab Placebo

Updated 17 times since 2017 Last updated: Jun 7, 2019 Started: Apr 11, 2014 Primary completion: Jul 17, 2018 Completion: Jul 17, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Alexion Pharmaceuticals, Inc.

More terminations from Alexion Pharmaceuticals, Inc.

Other Neuromyelitis Optica trials with similar outcome

Browse all Neuromyelitis Optica trials

Listed as NCT01892345, this PHASE3 trial focuses on Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder and remains terminated or withdrawn. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 17 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

17 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2023 — Jul 2024 [monthly]

Terminated PHASE3
Apr 2023 — Dec 2023 [monthly]

Terminated PHASE3

▶ Show 12 earlier versions

Dec 2021 — Apr 2023 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Jul 2019 — Jan 2021 [monthly]

Terminated PHASE3

Status: Completed → Terminated
Apr 2019 — Jul 2019 [monthly]

Completed PHASE3
Sep 2018 — Apr 2019 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Aug 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE3
Mar 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Oct 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Aug 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Feb 2017 — Aug 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexion Pharmaceuticals, Inc.

Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Ankara, Turkey (Türkiye) , Baltimore, United States , Barakaldo, Spain , Bunkyo-ku, Japan , Camperdown, Australia , Carlsbad, United States , Catania, Italy , Chiba, Japan , Ciudad Autonoma, Buenos Aires, Argentina and 53 more locations